TITLE

Hepatitis A vaccination in patients with chronic liver disease: to screen or not to screen?

AUTHOR(S)
Rothstein, Kenneth D.
PUB. DATE
July 2002
SOURCE
American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1590
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
No abstract available.
ACCESSION #
7839715

 

Related Articles

  • Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. Dumot, John A.; Barnes, David S.; Younossi, Zobair; Gordon, Steven M.; Avery, Robin K.; Domen, Ronald E.; Henderson, J. Michael; Carey, William D. // American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1601 

    OBJECTIVE: Hepatitis A can cause decompensation and death in patients with previous liver injury. The hepatitis A vaccine is recommended for patients with chronic liver disease. The aim of this study was to screen, immunize, and measure the safety and antibody response of the hepatitis A vaccine...

  • Hepatoma and chronic liver disease from maternally transmitted hepatitis B infection.  // Journal of Medical Screening;Mar1998, Vol. 5 Issue 1, p54 

    The article reports on the lifetime risk of death from hepatoma or chronic liver disease from maternally transmitted hepatitis B infection. It discusses the prevalence hepatitis B carriers in the antenatal population, its screening tests, the use of recombinant vaccine for intervention and the...

  • Hepatitis A, B vaccinations low in patients with chronic liver disease, diabetes. Friedman, Lawrence S. // Infectious Disease News;Jun2011, Vol. 24 Issue 6, p8 

    The article reports on a study which revealed that hepatitis A and hepatitis B vaccinations are low in patients with chronic liver disease and in those with type 2 diabetes.

  • Evaluation of the Hepatitis C Virus–Infected Patient: The Initial Encounter. Bräu, Norbert // Clinical Infectious Diseases;Mar2013, Vol. 56 Issue 6, p853 

    Chronic hepatitis C is a major cause of mortality from liver disease, but cure rates from antiviral treatments are improving. As expanded hepatitis C virus screening identifies more patients, infectious diseases physicians have a unique opportunity to be part of the cure.Deaths from hepatitis C...

  • Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Duncan, Marten; Hirota, William K.; Tsuchida, Amy // American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1792 

    OBJECTIVES:There are few prospective studies estimating the prevalence of hepatitis A in chronic liver disease patients. Furthermore, there are minimal cost-comparative data as to whether or not screening for hepatitis A exposure before immunization is an effective fiscal strategy. The...

  • Nonalcoholic Fatty Liver Disease in Chronic Hepatitis C. Patrick, Lyn // Townsend Letter;Apr2014, Issue 369, p67 

    The article addresses the question of whether all patients with diagnosed nonalcoholic fatty liver disease (NFLD) should be screened for chronic hepatitis C and whether all chronic hepatitis C patients should be screened for NASH (nonalcoholic steatotic hepatitis). In indicates an increased...

  • ATL>The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Jacobs, R. Jake; Koff, Raymond S.; Meyerhoff, Allen S. // American Journal of Gastroenterology;Feb2002, Vol. 97 Issue 2, p427 

    OBJECTIVES:Although hepatitis A vaccination is recommended for persons with chronic liver disease, the cost-effectiveness of vaccinating patients with chronic hepatitis C virus has not been extensively studied. We evaluated its costs and benefits.METHODS:A Markov model was used to assess...

  • Hepatitis C: Diagnosis and Treatment. WILKINS, THAD; MALCOLM, JENNIFER K.; SCHADE, ROBERT R. // American Family Physician;6/1/2010, Vol. 81 Issue 11, p1351 

    Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk...

  • Integrating Viral Hepatitis Screening and Prevention Services into an Urban Chemical Dependency Treatment Facility for American Indians and Alaska Natives. Huffman, Shelly; Brucker, Rachel; Redd, John T.; Taualii, Maile; Town, Cecile M.; Castor, Mei L.; Tetrick, Crystal C.; Forquera, Ralph; Buffington, Joanna // Journal of Health Disparities Research & Practice;Summer2011, Vol. 5 Issue 1, p32 

    American Indian/Alaska Natives (AI/AN) patients at an urban residential chemical dependency treatment center participated in a viral hepatitis prevention project. Project activities integrated into patients' treatment programs included viral hepatitis and human immunodeficiency virus (HIV) risk...

  • Hepatitis A vaccine tags on new indication.  // Drug Topics;7/7/97, Vol. 141 Issue 13, p7 

    States that SmithKline Beecham's Havrix (hepatitis A vaccine inactivated), has been approved for active immunization against the hepatitis A virus in patients with chronic liver disease. Information on how the hepatitis A virus is spread.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics